Specialty Pharma Journal Specialty, Precision & Technology
Berlin, December 3, 2018 – Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Pattern Recognition, which Bayer is currently developing jointly with MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA). A …
Tag Archives: Technology
December, 2018
November, 2018
-
21 November
HitGen and Biogen Enter a DNA-Encoded Library-Based Drug Discovery Research Collaboration
CHENGDU, China–(BUSINESS WIRE)–HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Biogen to identify novel small molecule leads for targets of interest. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover novel leads which …
-
14 November
Ferring Enters Exclusive Agreement with INVO Bioscience to Commercialize the Novel INVOcell System for Use in Treatment of Infertility
PARSIPPANY, N.J.–(BUSINESS WIRE)–Ferring Pharmaceuticals announced today that it has signed an agreement to acquire from INVO Bioscience Inc. (OTCQB:IVOB) the exclusive U.S. commercialization rights for the INVOcell intravaginal culture (IVC) system, which comprises the INVOcell IVC device, retention device, and holding block. The INVOcell IVC device uses a woman’s own body …
-
9 November
Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Obsidian Therapeutics, Inc., a biotechnology company developing cell therapies with pharmacologic operating systems, today announced the presentation of preclinical data demonstrating fine-tuned regulation of cytokine production and CAR-T function using Destabilizing Domains (DDs) paired with FDA-approved small molecule drugs. Obsidian will reveal a suite of novel human DDs …
October, 2018
-
30 October
Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna’s proprietary GalXC™ RNAi technology platform …
-
18 October
Amgen Invests $66 Million in Oxford Nanopore Technologies
THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen’s equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores …
-
18 October
Exact Sciences Strengthens Pipeline Capabilities With Acquisition of Biomatrica, A Leading Provider of Biological Sample Preservation Technology
MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica’s sample collection tubes, which contain proprietary, sample-stabilizing …
-
16 October
Scripps Research Translational Institute Collaborates with Seqster To Bring Genetic Risk Scores With Health Data
SAN DIEGO, Oct. 16, 2018 /PRNewswire/ — Seqster, the leading consumer-centric health data management platform empowering employees, members, or patients to collect, own and share all of their health data, today announced a collaboration with Scripps Research Translational Institute (“SRTI”), creators of the MyGeneRank app at the 2018 American Society …
-
3 October
Kite and HiFiBiO Collaborate to Develop Technology for Potential Discovery of Neoantigen-Reactive T Cell Receptors for the Treatment of Cancer
SANTA MONICA, Calif. & HONG KONG–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration and license agreement to develop technology supporting the discovery …
-
3 October
Dragonfly Collaborates with Merck to Develop Novel Drug Candidates for Solid Tumors Using Dragonfly’s TriNKET Platform
WALTHAM, Mass., Oct. 1, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly”), today announced a strategic collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers. The collaboration grants Merck the option to …